Combination of ASA with dabigatran or rivaroxaban increases risk of bleeding without additional benefit of stroke reduction in patients with atrial fibrillation

Authors

Anton Strunets, Advocate Aurora HealthFollow
Mahek Mirza, Advocate Aurora HealthFollow
Chris C. Cho, Advocate Aurora HealthFollow
Jasbir Sra, Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public HealthFollow
Arshad Jahangir, Advocate Aurora HealthFollow

Recommended Citation

Strunets A, Mirza M, Cho C, Sra J, Jahangir A. Combination of ASA with dabigatran or rivaroxaban increases risk of bleeding without additional benefit of stroke reduction in patients with atrial fibrillation. J Am Coll Cardiol. 2014;63(12 Suppl):A440.

Affiliations

Sheikh Khalifa bin Hamad Al Thani Center for Integrative Research on Cardiovascular Aging, Aurora UW Medical Group, Aurora Cardiovascular Services, Aurora Research Institute, Aurora Sinai/St. Luke's Medical Centers

Presentation Notes

Presented at ACC 2014 meeting in Washington, D.C.

Document Type

Poster